Kalli Sassaman, PA
Medical · Hot Springs, ARNPI 1538948484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,843, more than ten times the $142 reported in 2023.
Across 241 payments — averaging $15.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$708
- AstraZeneca$496
- Amgen$318
- Axsome Therapeutics, Inc.$316
- Antares Pharma, Inc.$198
- Lundbeck LLC$193
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,776100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $708 |
| AstraZeneca | 26 | $496 |
| Amgen | 25 | $318 |
| Axsome Therapeutics, Inc. | 14 | $316 |
| Antares Pharma, Inc. | 10 | $198 |
| Lundbeck LLC | 14 | $193 |
| Lilly USA, LLC | 15 | $188 |
| Dexcom, Inc. | 11 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $140 |
| Otsuka America Pharmaceutical, Inc. | 8 | $130 |
| Sumitomo Pharma America, Inc. | 9 | $125 |
| Boehringer Ingelheim | 7 | $112 |
| Vanda Pharmaceuticals Inc. | 5 | $95 |
| Pfizer | 6 | $94 |
| Novo Nordisk | 5 | $83 |
| Bayer | 4 | $71 |
| Supernus Pharmaceuticals, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Johnson & Johnson | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Astellas Pharma US Inc | 1 | $28 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Halozyme Inc | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $18 |
| Exact Sciences | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,776 in reported general payments places this provider in the 75th percentile of 133 medical providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $34,526 |
| OzempicSemaglutide | 11 | $11,287 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,357 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 81 | $1,380 |
| Pregabalin | 36 | $1,261 |
| Clonazepam | 51 | $416 |
| Levothyroxine Sodium | 33 | $320 |
| Omeprazole | 21 | $295 |
| Metoprolol Succinate | 21 | $282 |
| Doxycycline Hyclate | 22 | $275 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $274 |
| Tramadol Hcl | 59 | $249 |
| Tizanidine Hcl | 30 | $237 |
| Lisinopril | 44 | $202 |
| Mupirocin | 21 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $188 | $34,52632 claims |
| Novo NordiskOzempic | $83 | $11,28711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 medical providers in Arkansas.
Other medical in Hot Springs
- Dallas BondhusHot Springs$15K
- Emily VaughanHot Springs$2K
- Matthew ReynoldsRussellville$207K
- Tara BrunerSearcy$16K
- Douglas ClarkLittle Rock$14K
- Alexandra SanromaLittle Rock$11K
- Caleb MasonSearcy$9K
- Katherine McCradyLittle Rock$9K
- Bailey PollockLittle Rock$9K
- Hannah BreauLittle Rock$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.